scholarly journals Processing laboratory considerations for multi-center cellular therapy clinical trials: a report from the Consortium for Pediatric Cellular Immunotherapy

Cytotherapy ◽  
2020 ◽  
Author(s):  
Catherine Lindgren ◽  
Ashley Leinbach ◽  
Julie Annis ◽  
Jay Tanna ◽  
Nan Zhang ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Cellular Therapy ◽  
Cellular Immunotherapy

scholarly journals Clinical Trials with Combination of Cytokine-Induced Killer Cells and Dendritic Cells for Cancer Therapy

2019 ◽  
Vol 20 (17) ◽  
pp. 4307 ◽  
Author(s):  
Francesca Garofano ◽  
Maria A. Gonzalez-Carmona ◽  
Dirk Skowasch ◽  
Roland Schmidt-Wolf ◽  
Alina Abramian ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Dendritic Cells ◽  
Cellular Therapy ◽  
Residual Tumor ◽  
Allogeneic Transplantation ◽  
Cellular Immunotherapy ◽  
Adoptive Cellular Therapy ◽  
Surgical Ablation ◽  
Killer Cells ◽  
Cik Cells

Adoptive cellular immunotherapy (ACI) is a promising treatment for a number of cancers. Cytokine-induced killer cells (CIKs) are considered to be major cytotoxic immunologic effector cells. Usually cancer cells are able to suppress antitumor responses by secreting immunosuppressive factors. CIKs have significant antitumor activity and are capable of eradicating tumors with few side effects. They are a very encouraging cell population used against hematological and solid tumors, with an inexpensive expansion protocol which could yield to superior clinical outcome in clinical trials employing adoptive cellular therapy combination. In the last decade, clinical protocols have been modified by enriching lymphocytes with CIK cells. They are a subpopulation of lymphocytes characterized by the expression of CD3+ and CD56+ wich are surface markers common to T lymphocytes and natural killer NK cells. CIK cells are mainly used in two diseases: in hematological patients who suffer relapse after allogeneic transplantation and in patients with hepatic carcinoma after surgical ablation to eliminate residual tumor cells. Dendritic cells DCs could play a pivotal role in enhancing the antitumor efficacy of CIKs.

Cancer Immunotherapy in Children

2020 ◽  
pp. 64-70
Author(s):  
Koichi Hirabayashi ◽  
Gianpietro Dotti ◽  
Barbara Savoldo
Keyword(s):  
Clinical Trials ◽  
Stem Cell ◽  
Cancer Immunotherapy ◽  
Immune Cells ◽  
Haematopoietic Stem Cell Transplantation ◽  
Bispecific Antibodies ◽  
Haematopoietic Stem Cell ◽  
Cellular Immunotherapy ◽  
Tumour Associated Antigens ◽  
Inhibitory Molecules

This chapter discusses the principle of cancer immunotherapy in children and adolescents, starting with the most common form of cellular immunotherapy: allogeneic haematopoietic stem-cell transplantation (HSCT). It then discusses specific immunotherapy strategies based on the administration of classic monoclonal antibodies (mAbs) targeting tumour-associated antigens, novel bispecific antibodies that simultaneously target tumour-associated antigens and activate CD3+ T lymphocytes, and mAbs that block key inhibitory molecules of the immune system (checkpoint blockade). Finally, the chapter describes specific cellular immunotherapy approaches, such as tumour vaccine and adoptive transfer of immune cells. Although only a few immunotherapies have so far been incorporated into the standard practice for paediatric cancers, their role is enjoying a new revival, after the promising results obtained in recent clinical trials.

Clinical trials in cellular therapy

2007 ◽  
pp. 439-450
Author(s):  
Joanna Wykrzykowska ◽  
Munir Boodhwani ◽  
Roger Laham
Keyword(s):  
Clinical Trials ◽  
Cellular Therapy

scholarly journals Opportunities and challenges for the cellular immunotherapy sector: a global landscape of clinical trials

2017 ◽  
Vol 12 (6) ◽  
pp. 623-636 ◽  
Author(s):  
Katherine Bonter ◽  
Zackariah Breckenridge ◽  
Silvy Lachance ◽  
Jean-Sébastien Delisle ◽  
Tania Bubela
Keyword(s):  
Clinical Trials ◽  
Cellular Immunotherapy

Assessment of the efficacy of passive cellular immunotherapy for glioma patients

2020 ◽  
Vol 31 (4) ◽  
pp. 427-440
Author(s):  
Jun-Xia Cao ◽  
Wei-Jian Gao ◽  
Jia You ◽  
Li-Hua Wu ◽  
Zheng-Xu Wang
Keyword(s):  
Clinical Trials ◽  
T Cells ◽  
T Lymphocytes ◽  
Meta Analysis ◽  
Killer Cell ◽  
Cellular Immunotherapy ◽  
Cochrane Central Register ◽  
Autologous Tumor ◽  
Lymphokine Activated Killer Cells ◽  
Killer Cells

AbstractTo evaluate the therapeutic efficacy of passive cellular immunotherapy for glioma, a total of 979 patients were assigned to the meta-analysis. PubMed and the Cochrane Central Register of Controlled Trials were searched initially from February 2018 and updated in April 2019. The overall survival (OS) rates and Karnofsky performance status (KPS) values of patients who underwent passive cellular immunotherapy were compared to those of patients who did not undergo immunotherapy. The proportion of survival rates was also evaluated in one group of clinical trials. Pooled analysis was performed with random- or fixed-effects models. Clinical trials of lymphokine-activated killer cells, cytotoxic T lymphocytes, autologous tumor-specific T lymphocytes, chimeric antigen receptor T cells, cytokine-induced killer cells, cytomegalovirus-specific T cells, and natural killer cell therapies were selected. Results showed that treatment of glioma with passive cellular immunotherapy was associated with a significantly improved 0.5-year OS (p = 0.003) as well as improved 1-, 1.5-, and 3-year OS (p ≤ 0.05). A meta-analysis of 206 patients in one group of clinical trials with 12-month follow-up showed that the overall pooled survival rate was 37.9% (p = 0.003). Analysis of KPS values demonstrated favorable results for the immunotherapy arm (p < 0.001). Thus, the present meta-analysis showed that passive cellular immunotherapy prolongs survival and improves quality of life for glioma patients, suggesting that it has some clinical benefits.

Sign in / Sign up

Export Citation Format

Share Document